Slide 1: Financial Results - Fiscal Year 2019
Financial Results - Fiscal Year 2019 - May 18, 2020 JCR Pharmaceuticals co., Ltd. 【Securities code】 4552, 1st Sec. TSE Copyright © 2020 JCR Pharmaceuticals Co., Ltd. All rights reserved.
Slide 2: Financial Highlights (FY2019 results)
Financial Highlights (FY2019 results) Net sales reached a record high (8 consecutive years), but profit decreased due to a significant increase in R&D expenses (YoY) Net Sales: 24,781 million yen, Year-on-Year ＋7.0％ Operating Income: 3,244 million yen, YoY (34.7％) Ordinary Income: 3,293 million yen,
Slide 3: Consolidated Results
Consolidated Results (Unit: million yen) FY2018 FY2019 Reference (Apr. 1, 2018- Mar. 31, 2019) (Apr. 1, 2019- Mar. 31, 2020) Consolidated Year-on-Year Initial forecast A B (B-A)/A （before fixing） Net Sales 23,160 24,781 +7.0% 26,400 Cost of Sales 6,567 7,901 +20.3% 7,300 Gross Profit 16,592 16,880 +
Slide 4: Sales by Business Segments
Sales by Business Segments (Consolidated) (Unit: million yen) FY2018 FY2019 Name of business (Apr. 1, 2018- Mar. 31, 2019) (Apr. 1, 2019- Mar. 31, 2020) segment Composition Composition Year-on-Year Ａ ratio Ｂ ratio (B-A)/A Growject® 11,978 51.7% 12,650 51.0% +5.6% Epoetin Alpha BS Inj.[JCR] 4,511 19.
Slide 5: Trend in Sales by Business Segments (Consolidated)
Trend in Sales by Business Segments (Consolidated) 19 (Unit: million yen) 110 1,048 1,032 2,506 65 194 1,002 210 192 1,599 257 9 123 512 663 354 1,054 74 Other 817 1,527 1,625 27 558 1,412 License Revenue 228 1,052 989 828 17 Urine-derived products 586 958 2,272 725 Agalsidase Beta BS 427 317 2,345
Slide 6: Year-on-Year changes
Year-on-Year changes (Unit: million yen) ◆ Net Sales 24,781 million yen, Year-on-Year +1,621 million yen FY2018 23,160 Growject +672 Factors of change Epoetin Alpha BS △414 ・ Growject: Market penetration of Darbepoetin Alpha BS +1,412 Liquid formulation and strengthen promotional strategies TEMCELL
Slide 7: Financial Statement (Consolidated)
Financial Statement (Consolidated) (Unit: million yen) Mar. Mar. Main Mar. Mar. Main 2019 2020 increase/decrease 2019 2020 increase/decrease Short-term loans payable Cash and deposit Current 8,684 10,434 ＋1,250 ＋3,136 liabilities Account payable Current Accounts receivable 27,368 28,342 +356 assets
Slide 8: Trend in Balance Sheets (Consolidated)
Trend in Balance Sheets (Consolidated) (Unit: million yen) Assets Liabilities and net assets Investments and other assets Current liabilities Non-current liabilities Total net assets Equity ratio Intangible assets 75.0% Property, plant and equipment 71.1% 70.3% Current assets 66.6% 4,294 263 3,975 1
Slide 9: Cash Flows (Consolidated)
Cash Flows (Consolidated) (Unit: million yen) Operating Activities End of End of Increase/ Mar. 2019 Mar. 2020 decrease Investing Activities Ａ Ｂ Ｂ-Ａ Financing Activities Income before income Cash and Cash Equivalents at End of Period 4,928 3,422 (1,506) taxes 10,928 Depreciation and 1,343 1,434 +91
Slide 10: Trend in Cash Flows
Trend in Cash Flows (Consolidated) (Unit: million yen) FY2016 FY2016 FY2017 FY2017 FY2018 FY2018 FY2019 FY2019 1stH 2ndH 1stH 2ndH 1stH 2ndH 1stH 2ndH Operating Activities 1,909 1,909 742 742 1,830 1,830 1,303 1,303 2,372 2,372 1,533 1,533 2,949 2,949 1,978 1,978 Investing Activities (967) (967) 126
Slide 11: Trend in Gross profit margin
Trend in Gross profit margin (Unit: million yen) Products sales License Revenue Gross profit margin (Products sales) Gross profit margin (including License Revenue) 73.7% 70.8% 72.3% 71.8% 69.9% 66.9% 66.8% 65.1% 69.0% 67.1% 68.7% 67.5% 62.2% 64.9% 65.1% 65.6% 1,048 2,506 1,002 512 558 1,054 1,625 7
Slide 12: Trend in composition ratio of cost/expense
Trend in composition ratio of cost/expense Operating income R&D Expenses SG&A Cost of Sales 31.7% 29.8% 28.4% 31.9% 6,128 6,567 5,731 7,901 31.4% 31.4% 30.8% Above number (％) 32,7％ 6,469 7,270 7,638 rate of sales 5,919 Lower number (million yen) Amount of money 18.8% 20.5% 4,354 24.2% 22.5％ 4,211 4,
Slide 13: Forecast Highlights (FY 2020)
Forecast Highlights (FY 2020) Net Sales: 27,200 million yen, Year-on-Year + 9.8% Operating Income: 6,000 million yen, YoY +84.9% Ordinary Income: 6,000 million yen, YoY +82.2% Profit attributable to owners of parent: 4,800 million yen, YoY +79.2% Earnings Forecast ■ The sales of Growject®, treatment
Slide 14: FY2020 Forecast (Consolidated)
FY2020 Forecast (Consolidated) (Unit: million yen) FY2019 FY2020 Increase/ Year-on-Year (Apr. 1, 2019- (Apr. 1, 2020- Consolidated Mar. 31 2020) Mar. 31, 2021) decrease A B Ｂ-Ａ (B-A)/A Net sales 24,781 27,200 +2,418 +9.8% Cost of sales 7,901 6,800 (1,101) (13.9%) Gross profit 16,880 20,400 +3,519 +2
Slide 15: FY2020 Forecast (Consolidated) by segment
FY2020 Forecast (Consolidated) (Unit: million yen) FY2019 FY2020 forecast (Apr. 1, 2019-Mar. 31 2020) (Apr. 1, 2020- Mar. 31, 2021) Increase/ Name of Business decrease segment Composition Composition Ａ Ｂ (B-A) ratio ratio Growject® 12,650 51.0% 13,270 48.8% +620 Treatment for renal anemia 5,509 22.2
Slide 16: Correlation between R&D expenses and main R&D pipeline
Correlation between R&D expenses and main R&D pipeline (Unit: million yen) R&D Expenses (before deducting) Preclinical Clinical Filed an application 7,600 6,521 Approved 4,551 4,865 5,270 FY2016 FY2017 FY2018 FY2019 FY2020(Forecast) JR-141(Japan) Filed an application JR-141(Brazil) Filed an applicat
Slide 17: Forward-Looking Statement
FORWARD- LOOKING STATEMENT This presentation contains forward-looking statements that are subject to a number of risks and uncertainties, many of which are outside our control. All forward-looking statements regarding our plans, outlook, strategy and future performance are based on judgments derived
Slide 18: Copyright © 2020 JCR Pharmaceuticals Co., Ltd. All rights reserved.
Copyright © 2020 JCR Pharmaceuticals Co., Ltd. All rights reserved.